Olfactory Bulb Shrinkage Sign of Brain Aging and Disease

Olfactory Bulb Shrinkage: A Measurable Sign of Brain Aging and Disease

A systematic review of 29 brain imaging studies has quantified a direct link between the sense of smell and brain health. The research, led by Asghar A. and colleagues across multiple Indian medical institutes, found that the volume of the olfactory bulb—the brain’s smell processing center—shrinks predictably with age and more significantly in Parkinson’s and Alzheimer’s disease. This structural change correlates strongly with measurable loss in smell function, positioning olfactory decline as an early, physical indicator of neurodegeneration.

Brain Imaging Reveals a Shrinking Olfactory Center

The meta-analysis established clear baselines and disease-related deviations. In healthy adults, the pooled mean olfactory bulb volume measured approximately 55 cubic millimeters for each side of the brain. Using meta-regression, the team calculated a moderate negative correlation between bulb volume and age, with correlation coefficients ranging from -0.53 to -0.59. Simply put, the older a healthy person is, the smaller their olfactory bulb tends to be.

This physical shrinkage connects directly to function. The study found olfactory bulb volume was moderately correlated with scores on standardized smell tests, including the Threshold, Differentiation, and Identification (TDI) test and the University of Pennsylvania Smell Identification Test (UPSIT). The correlation coefficient was 0.48, providing imaging-based evidence that a smaller bulb means a weaker sense of smell.

Pathological shrinkage was even more pronounced. When comparing patients to healthy controls, the analysis found the olfactory bulb was reduced by 0.9 to 0.93 standard deviations in Parkinson’s disease and 1 to 1.05 standard deviations in Alzheimer’s disease. A key insight from the researchers is that a substantial portion—around 40%—of the bulb atrophy observed in Parkinson’s patients is likely due to the normal aging process itself, with the additional loss driven by the specific neurodegenerative pathology. This distinction is important for interpreting diagnostic scans.

Community Data Links Poor Smell Test Scores to Cognitive Risk

Supporting evidence comes from a community-based study of older adults led by Jacobsen E. at the University of Pittsburgh. This research moved beyond the clinic to examine real-world links between smell, cognition, and early disease markers. The study confirmed that poorer performance on smell identification tests was associated with lower cognitive scores and higher levels of plasma biomarkers for Alzheimer’s disease, such as p-tau181.

These findings suggest that a simple smell test could signal emerging neurological issues long before more severe symptoms like memory loss become apparent. The study’s community focus strengthens the argument that olfactory assessment is a practical tool for population-level health screening. It builds on the established science of how scent is wired to memory and emotion centers in the brain, a connection explored in our article on the science of the Proustian moment.

An important limitation in this field is that smell loss is not specific to just Parkinson’s or Alzheimer’s; it can result from other conditions like severe sinus disease, traumatic brain injury, or as noted in our review of a 2026 study on aneurysm surgeries, certain medical procedures. Furthermore, the olfactory decline associated with normal aging can sometimes mask early pathological signs.

Implications for Perfumers and Product Developers

For professionals in fragrance, this research underscores the biological importance of the olfactory system and its vulnerability. A significant segment of the aging population experiences a diminished sense of smell, which is not merely a sensory inconvenience but a potential window into brain health. This knowledge can inform more empathetic and effective product design.

Formulators may consider that for older users, particularly those in early stages of cognitive decline, scent perception is altered. A formula that relies on subtle, low-concentration top notes might be completely missed. This argues for creations with robust heart and base note structures, or the use of fragrance materials known for their potency and diffusiveness at the olfactory threshold. Understanding the chemistry of powerful, long-lasting ingredients, such as those discussed in our piece on vetiver’s impact on scent and chemistry, becomes even more relevant.

Beyond product aesthetics, this science highlights a potential new dimension for functional fragrance design. While no scent can cure neurodegeneration, the link between olfactory stimulation and cognitive engagement is clear. There is opportunity to explore how specific, well-defined accords might be used in environments aimed at cognitive support or sensory therapy, an area touched upon in our review of how scent can boost attention and memory.

Conclusion

Smell loss progresses from a natural age-related decline to a pronounced symptom of Parkinson’s and Alzheimer’s disease, with measurable shrinkage in the olfactory bulb visible on MRI scans. This positions olfactory function as a low-cost, non-invasive early warning system for neurological health. For the fragrance industry, it reinforces the need to tailor creations for an aging sensory landscape and to appreciate the profound neurological journey a scent molecule initiates.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42344186/
https://pubmed.ncbi.nlm.nih.gov/42189736/